ACE-031 and the ACVR2B Receptor: Mechanism and Pharmacology
ACE-031 is a soluble fusion protein consisting of the extracellular domain of the activin receptor type IIB (ACVR2B) linked to the Fc region of human immunoglobulin G1, engineered specifically to act as a ligand trap for myostatin and related TGF-β superfamily members. By functioning as a decoy receptor rather than a conventional small molecule, ACE-031 intercepts circulating myostatin (GDF-8), activin A, GDF-11, and BMP-9 before they can bind to and activate endogenous ACVR2B on muscle fibres. This upstream interception is the central pharmacological distinction that separates ACE-031 from follistatin analogues or myostatin propeptide strategies.
Myostatin itself operates through a well-characterised cascade: after binding ACVR2B, it recruits the co-receptor ALK-4 or ALK-5, triggering SMAD2/SMAD3 phosphorylation, which in turn transcriptionally represses anabolic pathways and upregulates atrophy-associated ubiquitin ligases such as MuRF1 and atrogin-1. ACE-031 sequesters myostatin with a reported binding affinity (Kd) in the low picomolar range, effectively preventing SMAD2/3 phosphorylation in skeletal muscle at concentrations achievable with a single subcutaneous administration. In clinical-stage research conducted by Acceleron Pharma, a single subcutaneous dose of 1–3 mg/kg in healthy volunteers produced measurable increases in lean mass within weeks, alongside transient reductions in serum FSH — an expected off-target signal given the broader activin-suppressing activity of the molecule.
The plasma half-life of ACE-031 following subcutaneous injection is estimated at approximately 10–14 days in humans, consistent with IgG1-Fc fusion proteins generally. Subcutaneous bioavailability for Fc-fusion biologics of this class typically ranges from 50–70%, meaning that effective systemic exposure can be achieved without intravenous administration. Peak serum concentrations are reached roughly 3–5 days post-injection. Because ACE-031 is a large-molecular-weight protein (approximately 100 kDa as a dimer), it is not orally bioavailable and requires reconstitution and injection for research use. These pharmacokinetic parameters directly inform dosing interval considerations within experimental protocols.
Application Context and User Groups in Research Settings
ACE-031 occupies a specific and well-defined niche within the landscape of peptide and protein research. Its primary application context is the investigation of myostatin pathway blockade in models of muscle wasting, sarcopenia, muscular dystrophy, and cachexia — fields where myostatin suppression is considered a validated therapeutic target following decades of preclinical and clinical evidence. The original Phase 1/2 trials in Duchenne muscular dystrophy patients demonstrated statistically significant increases in whole-body lean tissue mass, providing some of the most compelling human-context data for any ACVR2B-targeting agent to date.
Within the performance research community, ACE-031 attracts interest because myostatin suppression addresses a fundamental biological ceiling on skeletal muscle hypertrophy. Satellite cell activation, myofibrillar protein synthesis, and net muscle fibre growth are all negatively regulated in part by myostatin signalling; a ligand trap that neutralises this brake point therefore represents a mechanistically distinct approach compared to androgen receptor agonists or IGF-1 pathway compounds. Researchers and advanced practitioners exploring body-composition modelling recognise that ACE-031 binds the ACVR2B ligand family rather than androgen pathways, meaning it operates without direct interaction with the hypothalamic-pituitary-gonadal axis — an important distinction for study design.
The user profile for ACE-031 in research settings skews toward those with familiarity in reconstituting lyophilised proteins, experience with peptide injection protocols, and an understanding of the TGF-β superfamily's pleiotropic effects. Because ACE-031 also sequesters activin A — which modulates FSH release from the pituitary — researchers should be aware that endocrine readouts may be transiently affected. Haematological parameters warrant monitoring in extended protocols, as activin ligands also influence erythropoiesis. ACE-031 is strictly a research compound, and all use should occur within appropriate regulatory and institutional frameworks. This is not a medical recommendation.
Range & Selection by Concentration and Pack Size
10 mg/Vial — Single-Vial Research Units
The current category offering comprises the 10 mg/vial concentration tier, supplied as single-vial packs. This concentration reflects the practical reality of ACE-031's potency profile: at typical research dosing benchmarks extrapolated from clinical literature (roughly 1–3 mg/kg bodyweight used in clinical trials, often scaled downward for investigative use), a 10 mg lyophilised vial provides a meaningful research quantity while remaining manageable for cold-chain storage and single-session use.
The representative product in this tier is ACVR2B (ACE-031) 10mg/vial 1 Vial by Bio-Peptide. Bio-Peptide is a manufacturer associated with peptide and protein research reagents, offering this compound in lyophilised powder form, which provides stability during storage. Lyophilisation is particularly important for a complex Fc-fusion protein like ACE-031, as the native molecule is sensitive to temperature fluctuations and degradation in aqueous solution. Researchers should reconstitute with bacteriostatic water and store the resulting solution refrigerated at 2–8 °C, using within a defined window appropriate to the manufacturer's specifications.
For those beginning to work with ACVR2B-pathway research, a single 10 mg vial is a logical starting point: it allows protocol design and baseline measurement before committing to larger quantities. For those engaged in longer-duration comparative studies, planning multi-vial procurement from the outset is advisable, as consistency of batch and manufacturer is important for experimental reproducibility. At this stage, only the 10 mg concentration is listed, making the purchasing decision straightforward; however, researchers should confirm their institutional approvals and cold-chain logistics prior to ordering.
Frequently Asked Questions
What is ACE-031 and how does it differ from myostatin antibodies?
ACE-031 is a soluble ACVR2B-Fc fusion protein that acts as a decoy receptor, capturing myostatin and related ligands before they reach endogenous receptors. Unlike monoclonal antibodies targeting myostatin alone, ACE-031 neutralises the broader activin ligand family — including activin A and GDF-11 — making it a wider-spectrum inhibitor of the TGF-β superfamily with correspondingly broader physiological effects in research models.
Why is ACE-031 supplied in lyophilised powder form rather than pre-mixed solution?
As a large Fc-fusion protein of approximately 100 kDa, ACE-031 is significantly less stable in aqueous solution than small-molecule peptides. Lyophilisation removes moisture, dramatically extending shelf stability and making cold-chain transport more forgiving. Researchers reconstitute the powder with bacteriostatic water immediately before use, ensuring the protein retains its structural integrity and binding activity at the point of application.
What half-life should researchers account for when designing ACE-031 dosing intervals?
The plasma half-life of ACE-031 is estimated at approximately 10–14 days in humans, consistent with IgG1-Fc fusion biologics. This extended half-life — a direct consequence of FcRn-mediated recycling of the IgG Fc domain — means that biological activity persists well beyond the injection event. Research protocols typically incorporate dosing intervals of two to four weeks to avoid accumulation beyond intended exposure levels.
Lab Tested